** Shares of medical device maker NeuroPace NPCE.O fall 15% to $15.02 premarket
** Co, citing preliminary data, says neuromodulation therapy for a group of genetic epilepsy syndromes failed to meet main efficacy goal in the overall population in a 2-year study
** The device, RNS System, is implanted in the skull to constantly monitor brain waves, identifying and disrupting unusual activity that may trigger seizures
** The device, however, showed significant efficacy in a subset of patients, which represents the majority of participants - NPCE
** It is approved in the U.S. to treat focal epilepsy, a type of seizure that affects only one side of the brain and body
** Up to last close, stock up ~58% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。